Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1
International Journal of Molecular Medicine · 2024
DOI: 10.3892/ijmm.2024.5451 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, 2024. Verfasst von Boren Tian und 3 weiteren Autor:innen. Beteiligte Einrichtung: MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat‑sen University, Guangzhou, Guangdong 510275, P.R. China. Hauptthemen laut MEDLINE: Osteosarcoma, Dynamins, Neoplastic Stem Cells, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Osteosarcoma malignancy exhibits significant heterogeneity, comprising both osteosarcoma stem cells (OSCs) and non‑OSCs. OSCs demonstrate increased resistance to chemotherapy due to their distinctive cellular and molecular characteristics. Alterations in mitochondrial morphology and homeostasis may enhance chemoresistance by modulating metabolic and regulatory processes. However, the relationship between mitochondrial homeostasis and chemoresistance in OSCs remains to be elucidated. The present study employed high‑resolution microscopy to perform multi‑layered image reconstructions for a quantitative analysis of mitochondrial morphology. The results indicated that OSCs exhibited larger mitochondria in comparison with non‑OSCs. Furthermore, treatment of OSCs with cisplatin (CIS) or doxorubicin (DOX) resulted in preserved mitochondrial morphological stability, which was not observed in non‑OSCs. This finding suggested a potential association between mitochondrial homeostasis and chemoresistance. Further analysis indicated that dynamin‑related protein 1 (DRP1) might play a pivotal role in maintaining the stability of mitochondrial homeostasis in OSCs. Depletion of DRP1 resulted in the disruption of mitochondrial stability when OSCs were treated with CIS or DOX. Additionally, knocking out DRP1 in OSCs led to a reduction in chemoresistance. These findings unveil a novel mechanism underlying chemoresistance in osteosarcoma and suggest that targeting DRP1 could be a promising therapeutic strategy to overcome chemoresistance in OSCs. This provided valuable insights for enhancing treatment outcomes among patients with osteosarcoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- MOE Key Laboratory of Gene Function and Regulation, School of Life Sciences, Sun Yat‑sen University, Guangzhou, Guangdong 510275, P.R. China.
Zitieren
APA
Tian, B., Wu, Y., Du, X., & Zhang, Y. (2024). Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1. International Journal of Molecular Medicine. https://doi.org/10.3892/ijmm.2024.5451
Vancouver
Tian B, Wu Y, Du X, Zhang Y. Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1. International Journal of Molecular Medicine. 2024. doi:10.3892/ijmm.2024.5451
BibTeX
@article{Tian2024,
author = {Tian, Boren and Wu, Yaxuan and Du, Xiaoyun and Zhang, Yan},
title = {Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1},
journal = {International Journal of Molecular Medicine},
year = {2024},
doi = {10.3892/ijmm.2024.5451}
}
EUVIMED